Speaker Bios

 

*Mace L. Rothenberg, MD, Senior Vice President, Clinical Development & Medical Affairs, Oncology Business Unit, Pfizer, Inc.

Dr. Rothenberg oversees the clinical research and development activities as well as post-marketing evaluation and monitoring for all oncology products at Pfizer. He came to Pfizer in 2008 after more than 20 years in academia where he focused on early-stage drug development, clinical trial design and the coordinated laboratory-clinical evaluation of new therapies for gastrointestinal cancers.┬ Dr. Rothenberg's work was critical to the development and eventual FDA approval of irinotecan (CPT-11, Camptosar┬«) in 1996 and oxaliplatin (Eloxatin┬«) in 2002 for colorectal cancer and gemcitabine (Gemzar®) in 1996 for pancreatic cancer.